A Phase II Study to evaluate progression free survival following Everolimus treatment in Patients with FDG-PET positive intermediate grade (Ki-67 3-20%) Pancreatic Neuroendocrine Tumours (PNETs)
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Everolimus (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms INTERNET
- Sponsors Novartis
- 30 Jun 2016 New trial record